GSK Fail-to-Deliver

GSK plc (GSK) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry, with a market capitalization near $92.70B, listed on NYSE, employing roughly 66,841 people, carrying a beta of 0.28 to the broader market. GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Led by Luke Victor Miels, public since 1980-03-28.

Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.

Latest Date
2026-09-04
Latest FTD Quantity
999
Latest Price
$50.87
30-Day Avg FTD
28.5K
30-Day Total FTD
854.9K

Showing 30 days of SEC fail-to-deliver data for GSK plc.

Learn how fails-to-deliver is reported and how to read the data →

Frequently asked GSK fail to deliver questions

What is the latest GSK fail-to-deliver count?
As of Sep 4, 2026, GSK plc (GSK) fail-to-deliver quantity is 999 shares, with a 30-day average of 28.5K shares. The SEC publishes FTD data twice monthly: first-half data at month-end, second-half around the 15th of the following month.
What is the FTD aggregate net balance?
FTD figures represent the aggregate net balance in NSCC's Continuous Net Settlement (CNS) system, not the gross failed-share count. The published numbers run 2-6 weeks stale relative to the underlying settlement date.
How do GSK FTDs affect options pricing?
Persistent FTDs flag hard-to-borrow conditions that distort put-call parity: in HTB names, synthetic long stock (long call + short put at the same strike) trades below the frictionless-parity price by approximately the borrow rebate. The discount equals the lending revenue forgone by holding the synthetic instead of actual shares. Reg SHO threshold-list inclusion follows from sustained FTD persistence.